NeoGenomics Laboratories

We hope your day is filled with good food, fun, and time spent with loved ones. #HappyThanksgiving 🍁🦃

c-MET for NSCLC IHC testing can help determine eligibility for a new second-line targeted therapy—empowering informed treatment decisions. Add c-MET CDx for NSCLC IHC to your PanTracer Tissue orders today: https://lnkd.in/gEZn74Dd #Oncology #NSCLC #cMETCDx #EGFRwildtype

MRD is redefining oncology clinical trial design. Learn how in our upcoming webinar. Register now: https://lnkd.in/e8dniUHg. In this webinar, Tim Forshew, PhD, and Amber Chevalier will share how RaDaR® ST, NeoGenomics’ latest tumor-informed MRD solution, delivers: • Real-time insights into tumor dynamics • Optimized clinical trial design • Real-world impact of MRD utilization in oncology pipelines #OncologyInnovation #MRD #RaDaR #ClinicalTrials #NeoGenomicsPharma #PrecisionMedicine

Better data leads to better decisions. This collection of white papers showcases how molecular insights are driving the next generation of oncology solutions. Dive into the details: https://bit.ly/47xegrL #NGS #Biomarkers #OncologySolutions #NeoGenomics

Register for Metastatic Outcomes in Lung Cancer Using Comprehensive Genomic Profiling: https://lnkd.in/g9WrTFjA? This webinar will explore the complementary roles of tissue-based and liquid biopsy–based CGP in the management of patients with non–small cell lung cancer (NSCLC). Faculty experts will review the latest clinical evidence, discuss real-world case applications, and highlight best practices for integrating both modalities into routine care.

Don’t miss this informative series discussing the value of implementing complementary CGP testing workflows for advanced lung cancer. #Oncology #OncView

We are presenting new data at the 67th ASH® Annual Meeting and Exposition! 🔗 https://lnkd.in/g6wuWyMf 📍Visit abstract # 6410 on Monday, December 8, to learn how real-world data and comprehensive genomic profiling, such as Neo Comprehensive® - Myeloid Disorders, are essential for understanding diagnostic and treatment patterns, identifying critical genomic variants, and guiding personalized care across diverse myeloid malignancies. • Session Name: 908. Outcomes Research: Myeloid Malignancies: Poster III • Session Date: December 8, 2025 • Presentation Time: 6:00 PM - 8:00 PM • Room: OCCC - West Halls B3-B4

From biopsy to blood draw, PanTracer™ is an advanced CGP assay that detects genomic alterations relevant to therapy selection and clinical trial enrollment: https://lnkd.in/gf2YbMyb

See what’s new from NeoGenomics at #ASH25! 🔗 https://lnkd.in/g6wuWyMf • Neo Comprehensive® - Myeloid Disorders – A solution to identify critical genomic variants and guide personalized care across diverse myeloid malignancies. • Compass – Our comprehensive, pathologist-guided service delivers personalized, actionable insights across 100+ hematologic malignancies to arrive at a definitive diagnosis for every patient. • AML Express – Accelerate clinical decisions with rapid, detailed genetic insights for precise diagnosis and tailored treatment. Better AML outcomes start with faster, informed decisions.

Oncology drug development is complex. NeoGenomics makes it simpler. 🔗 https://lnkd.in/gYGvm4ER With 10+ years of expertise and 300+ biopharma partners supported, we deliver precision, speed, and confidence across the therapeutic journey. Let’s connect and accelerate breakthroughs together. #OncologyInnovation #NeoGenomics #PharmaServices